Shore Neal D, Morgans Alicia K, Tutrone Ronald F
CPI - Carolina Urologic Research Center, Myrtle Beach, SC 29572, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Future Oncol. 2024 Dec;20(39):3179-3182. doi: 10.1080/14796694.2024.2418279. Epub 2024 Nov 18.
While suppressing testosterone to castration levels is the aim of androgen deprivation therapy for the treatment of advanced prostate cancer, studies have shown that prolonged low testosterone levels can have negative effects on patients' overall health and quality of life. This podcast covers two recently published papers that examined testosterone recovery in different ways. One real-world study assessed the impact of delayed testosterone recovery on clinical outcomes in patients with prostate cancer. A second subgroup analysis of the HERO trial assessed rates of testosterone recovery in patients receiving the long-acting, injectable gonadotropin-releasing hormone receptor agonist, leuprolide or the oral, once-daily gonadotropin-releasing hormone receptor antagonist, relugolix.
虽然将睾酮抑制到去势水平是晚期前列腺癌雄激素剥夺治疗的目标，但研究表明，长期低睾酮水平会对患者的整体健康和生活质量产生负面影响。本期播客涵盖了两篇最近发表的以不同方式研究睾酮恢复情况的论文。一项真实世界研究评估了睾酮恢复延迟对前列腺癌患者临床结局的影响。HERO试验的第二项亚组分析评估了接受长效注射用促性腺激素释放激素受体激动剂亮丙瑞林或口服每日一次促性腺激素释放激素受体拮抗剂relugolix的患者的睾酮恢复率。
